The Flow has not summarised this story yet — read it at arXiv Computer Vision.
EXPOSE is a framework that applies Sparse Autoencoders to Vision Foundation Model embeddings in computational pathology, aiming to separate biological signals from domain‑specific noise. By training a sparse representation of VFM features and using a linear classifier to flag domain‑specific latent dimensions, the method masks these components before downstream relapse prediction, avoiding the need to retrain the backbone model. Experiments on a large prostate cancer dataset demonstrate that removing domain‑specific features improves cross‑domain performance and raises the Domain Robustness Index (DoRI).
arXiv:2603.23794v2 Announce Type: replace Abstract: Vision foundation models (FMs) achieve state-of-the-art performance in medical imaging. However, they encode information in abstract latent represe...
Recent advances in pathology foundation models have enabled accurate prediction of spatial transcriptomics (ST) from routine H&E images. However, existing explainability methods for vision transformer...
arXiv:2610.33059v1 Announce Type: cross Abstract: Pathology foundation models (PFMs) differ substantially in architecture, pretraining objective, training data and representation dimensionality, yet...
HERO (Histology Encoder for Robust Representation in Oncology) is a ViT‑G/14 pathology foundation model trained with DINO and iBOT objectives and refined using high‑resolution Gram anchoring on a 500‑million‑tile corpus from about 575,000 clinical whole‑slide images. It demonstrates superior robustness to center, scanner, and stain variation compared to other state‑of‑the‑art foundation models, while maintaining competitive performance on tile‑level classification, segmentation, and gene‑expression prediction. Across 39 slide‑level clinical tasks, HERO ranks first on average and achieves the best average rank across six benchmark frameworks under an equal‑weighted analysis.
arXiv:2608. 13939v1 Announce Type: cross Abstract: Ultrasound is the primary imaging modality for assessing thyroid nodules, and the ACR TI-RADS framework standardizes diagnosis through five ultrasound feature categories that are aggregated into five risk levels (TR1-TR5).